Results 41 to 50 of about 25,082 (343)
AbstractNeprilysin (NEP) is a transmembrane zinc‐dependent metalloproteinase that inactivates various peptide hormones including glucagon‐like peptide 1 (GLP‐1). NEP inhibitors may be effective in the management of type 2 diabetes mellitus (T2DM) by increasing the circulating level of GLP‐1.
Faisal Holil AlAnazi+8 more
openaire +2 more sources
BackgroundAlthough the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF) treatment, less is known about the tissue-level effects of the drug on the atrial myocardial functional reserve and ...
Uwe Primessnig+27 more
doaj +1 more source
Serum neprilysin levels are elevated in preeclampsia
To evaluate the possible associations between serum Neprilysin (NEP) levels and preeclampsia and mild and severe preeclampsia subgroups.Fifty-five consecutive women with mild preeclampsia and fifty-five consecutive women with severe preeclampsia were compared with 110 approximately gestational age-matched (±1 week) women with an uncomplicated pregnancy.
Tüten, Nevin+8 more
openaire +6 more sources
Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization [PDF]
Background: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates ...
Claggett, Brian L.+11 more
core +2 more sources
Chronic hypoxia has been postulated as one of the mechanisms involved in salt-sensitive hypertension and chronic kidney disease (CKD). Kidneys have a critical role in the regulation of arterial blood pressure through vasoactive systems, such as the renin-
Carlos P. Vio+8 more
doaj +1 more source
Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham+18 more
core +3 more sources
Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition
Background: Current Heart failure (HF) pharmacotherapy has been unsatisfactory in halting disease progression completely. Aims and Objective: To evaluate the role of LCZ696, a recent FDA-approved ACE -Neprilysin inhibitor (ARNi) in the management of ...
Sandeep Lahiry
doaj +1 more source
Tripchlorolide attenuates β-amyloid generation by inducing NEP activity in N2a/APP695 cells
Alzheimer’s disease (AD) is a neurodegeneration disease. The previous work from our research group demonstrated the neuroprotective effects of tripchlorolide (T4) in AD animal models.
Zeng Yuqi+4 more
doaj +1 more source
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF [PDF]
Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders.
Chen, Chen-Huan+16 more
core +3 more sources
Angiotensin receptor blocker neprilysin inhibitors
Heart failure (HF) is a clinical syndrome that results from a structural or functional cardiac disorder that reduces the ability of the ventricle of the heart to fill with, or eject, blood. It is a multifaceted clinical condition that affects up to 2% of the population in the developed world, and is linked to significant morbidity and mortality; it is ...
Suguru Asako+18 more
openaire +3 more sources